Introduction
Vesicoureteral reflux (VUR), the most common urologic anomaly in pediatrics, affects 1% of children and may be present in 30-50% of those who present with urinary tract infection [1 • ,2]. Although mild cases of VUR may resolve spontaneously, in severe cases the combination of reflux, recurrent pyelonephritis, and renal scarring may lead to hypertension, renal impairment, and eventually renal failure [1 • ,3]. To prevent these complications, VUR must be identified and treated appropriately. Early treatment often consists of antibiotic prophylaxis to allow for spontaneous resolution, especially in grade I and II disease. Long-term antibiotic prophylaxis carries a risk of developing resistant bacteria, noncompliance with therapy, and a minimal risk of continued renal scarring [4, 5] . Although open surgical repair is highly effective for treatment, with a success rate of 98%, it is an invasive procedure associated with complications and generally a hospital stay of 2-5 days [5] . For these reasons, O'Donnell and Puri [6] developed the subureteric polytetrafluoroethylene (Teflon; Dupont, Wilmington, DE) injection (STING) procedure as a minimally invasive approach to the treatment of VUR in 1984. This section of our review focuses on recent publications in the urology literature from February 2002-October 2004 that discuss the endoscopic management of VUR. In the final section of the paper, we highlight articles on the role of subspecialized care and surgical outcomes in children.
Subureteric polytetrafluoroethylene (Teflon) injection
The pathophysiology of VUR is an incomplete muscular backing of the ureteral tunnel allowing urine to reflux through the ureteral orifice proximally toward the kidney. Antireflux surgery corrects this anatomic abnormality by increasing the tunnel length via ureteral reimplantation, providing more muscular backing and creating a flap-valve to compress the ureter as the bladder fills. STING procedures recreate the flap-valve mechanism by injecting a bulking agent beneath the ureteral orifice, effectively closing the distal ureter. The appearance of the ureteral orifice assumes a 'volcanic cone' or nipplelike shape with a crescentic slit [6]. The STING procedure has been performed in Europe in this manner for the past two decades, but acceptance was slower in the United States secondary to safety concerns regarding the bulking agent.
The ideal bulking agent is a biodegradable, nonabsorbed, inexpensive material with no allergenic, immunogenic, or carcinogenic potential. Teflon was the first bulking agent used; however, animal studies demonstrated migration of the material through lymphatics and capillaries to distant organs, including the central nervous system. Despite its continued use in Europe, the safety concerns of possible migration limited its use in the United States. Several different agents have been used, including autologous blood, autologous chondrocytes, and cross-linked bovine collagen, but each has downsides when compared with the ideal bulking agent [7] [8] [9] . In 2001, the US Food and Drug Administration approved the use of dextranomer/hyaluronic acid copolymer (Dx/HA) for the endoscopic treatment of VUR. Dx/HA is a biodegradable, organic substance created by suspending 80-mm to 250-mm dextranomer 'microspheres' in a sodium hyaluronic acid solution [2] . Although expensive, to date Dx/HA is the most used and most studied bulking agent in the United States and is thus the focus of this review.
Outcomes of subureteric Teflon injection using dextranomer copolymer
O'Donnell and Puri [6] developed the STING procedure in Dublin, Ireland, in 1984. Puri et al.
[2] prospectively studied the use of Dx/HA in 113 children with 166 affected ureters (54 bilateral cases). Eighty-one girls and 32 boys between 3 months and 10 years of age with primary VUR grades II to V underwent endoscopic injection with Dx/HA. Indications for treatment were similar to open surgery, including high-grade reflux, recurrent urinary tract infection on chemoprophylaxis, and progressive scarring visible on radionuclide scans. Prophylaxis was continued 12 weeks after injection. Voiding cystourethrography (VCUG) and renal ultrasounds were performed at 3 months and 1 year after injection. The study is ongoing, but early results with a median follow-up of 6 months demonstrate correction of reflux in 143 of the 166 ureters, or 86%, after a single injection. Twenty-two patients required a second injection to resolve their reflux and one patient required a third injection for correction. All patients were discharged on the day of surgery and there were no complications from surgery [2] .
Although a 100% cure rate is encouraging and equivalent to surgery, the authors do not clearly define 'correction'. Several European studies define 'correction' as a reduction in reflux to grade 0 or 1 on the International Reflux Classification. In addition, only 11 of the 113 patients had completed the 1-year follow-up, meaning most of the authors' results are based on only one postoperative VCUG at 3 months. Other studies have shown that most relapses occur within the first year, but they can occur up to 3 years after injection [1 • ]. The study is promising and the long-term results from their institution are anxiously anticipated.
Capozza et al. [1 • ] from Rome, Italy, have also been using the STING procedure for several years. They recently retrospectively reviewed more than 1000 patients treated with endoscopic injection. Since 1995, 788 patients with 1050 ureters have undergone a STING with Dx/HA for VUR grades II-IV. The children were often discharged home 24 hours after treatment and prophylaxis was continued for 1 month after injection. VCUGs were obtained at 3 and 12 months routinely and renal ultrasounds were done once a year. Length of follow-up was a minimum of 12 months, with an average of 7.5 years. Overall success rate (defined as grade 0-I reflux) for Dx/HA was 82% for all grades and 92, 80, and 57% for grades II, III, and IV-V, respectively. Two complications occurred: prolonged, severe hematuria in one child and temporary obstruction of the ureterovesical junction in eight patients. The authors note that the success rate of endoscopic treatment is significantly reduced by the presence of abnormal voiding habits and recommend correction of voiding dysfunction prior to surgical management. They conclude that endoscopic injection may be a reasonable alternative to antibiotic prophylaxis as a first-line therapy for VUR [1 • ]. Although Food and Drug Administration approval for Dx/HA is for simple VUR from grades II-IV, there have been early results for use in complex cases of reflux including duplicated systems; small, minimally functioning kidneys; persistent reflux following open surgery; and other complex ureteral anatomy [11, 12] . Lackgren et al. [11] report a positive response (reflux grade 0-I) in 63% in children with duplex ureters (68 patients) and a 70% positive response in children with a small kidney (40 patients). Perez-Brayfield et al. [12] studied 55 girls and 17 boys with a total of 93 ureters treated for complex reflux. Persistent reflux following open surgery, duplication, neurogenic bladder, and retained ureteral stumps were just a few of the indications for endoscopic injection. The overall success rate for 69 patients with 3 months' follow-up data was 68% after one injection. Their largest group, 17 patients with persistent reflux after failed open surgery, demonstrated a success rate of 88% for one injection [12] . These studies are encouraging for the use of endoscopic management in complex circumstances.
Paradigm shifts
Endoscopic management of VUR is popular among parents and practitioners because it is an effective outpatient procedure [13] . STING with Dx/HA has proven successful in initial studies with an overall success rate of 82-86% with initial injection. These early results have led to many questions regarding the best management of reflux. The American Urologic Association Guidelines for Reflux does not list endoscopic therapy as a recommended treatment for VUR secondary to the lack of long-term data demonstrating efficacy. Parents desire an easy alternative to daily prophylactic antibiotics but consider open surgery almost as the last resort [13] . A recent detailed costeffectiveness model predicted that a persistent approach to endoscopic surgery would achieve results equal to or exceeding that of open surgery, at a lower cost [5] . The data promoting endoscopic management are impressive; however, criticism abounds.
First, the direct comparisons to surgery are often faulty as the definition of success between the two therapies is often different. Persistent reflux is just that-persistent reflux. To call grade I reflux a success is misleading compared with complete surgical cure with no reflux and a success rate of 98%. Second, to initiate endoscopic management as the first-line therapy above antibiotic prophylaxis would mean overly aggressive treatment in a few patients in whom reflux would spontaneously resolve. This would certainly increase the overall cost of VUR management in the long term. Lastly, the belief that open surgery requires prolonged hospitalization is also changing.
Our institution has completed a prospective trial of unilateral extravesical reimplantation performed on an outpatient basis, which has been submitted for publication. Briefly, a total of 80 children were enrolled in the study with 20 children serving as inpatient controls, whereas 60 children underwent reimplantation procedures on an outpatient basis. The average length of stay for inpatients was 36 hours vs 6.6 hours for the outpatients. Of the 60 outpatients, four required same-day admission or admission on the first postoperative day for failure to meet discharge criteria or inadequate pain control. We can therefore achieve a 98% successful and curative outcome using the outpatient process in a similar manner to endoscopic injection (Putman et al., pending publication).
Conclusion
Urology has seen a paradigm shift in recent years toward endoscopic management of primary VUR and even more difficult cases of complex reflux. Although long-term studies are emerging for Dx/HA as the bulking agent of choice, we are unable to predict the success of endoscopic treatment into adulthood. More outcomes data are needed before accurate comparisons can be made. 'Success' must be defined similarly for all treatment modalities to make accurate comparisons. Until then, endoscopic injection remains a promising treatment for reflux, but open surgery remains the gold standard. Subspecialization delivers the most costeffective and efficacious outcomes for children across all surgical disciplines.
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